SK282947B6 - Použitie interleukínu-10 alebo jeho analógu, agonistu alebo antagonistu na výrobu farmaceutického prostriedku - Google Patents

Použitie interleukínu-10 alebo jeho analógu, agonistu alebo antagonistu na výrobu farmaceutického prostriedku Download PDF

Info

Publication number
SK282947B6
SK282947B6 SK129-94A SK12994A SK282947B6 SK 282947 B6 SK282947 B6 SK 282947B6 SK 12994 A SK12994 A SK 12994A SK 282947 B6 SK282947 B6 SK 282947B6
Authority
SK
Slovakia
Prior art keywords
cells
lps
mice
tnfα
ifnγ
Prior art date
Application number
SK129-94A
Other languages
English (en)
Slovak (sk)
Other versions
SK12994A3 (en
Inventor
Waal Malefyt Rene De
Maureen Howard
Di-Hwei Hsu
Hiroshi Ishida
Anne O'garra
Hergen Spits
Albert Zlotnik
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of SK12994A3 publication Critical patent/SK12994A3/sk
Publication of SK282947B6 publication Critical patent/SK282947B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SK129-94A 1991-08-06 1992-08-06 Použitie interleukínu-10 alebo jeho analógu, agonistu alebo antagonistu na výrobu farmaceutického prostriedku SK282947B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74212991A 1991-08-06 1991-08-06
PCT/US1992/006378 WO1993002693A2 (fr) 1991-08-06 1992-08-06 Utilisation d'analogues ou d'antagonistes de l'interleukine-10 pour traiter la toxicite induite par l'endotoxine ou un superantigene

Publications (2)

Publication Number Publication Date
SK12994A3 SK12994A3 (en) 1994-12-07
SK282947B6 true SK282947B6 (sk) 2003-01-09

Family

ID=24983602

Family Applications (1)

Application Number Title Priority Date Filing Date
SK129-94A SK282947B6 (sk) 1991-08-06 1992-08-06 Použitie interleukínu-10 alebo jeho analógu, agonistu alebo antagonistu na výrobu farmaceutického prostriedku

Country Status (17)

Country Link
EP (2) EP0600970B1 (fr)
JP (3) JPH07502019A (fr)
KR (1) KR100271197B1 (fr)
AT (1) ATE187336T1 (fr)
AU (1) AU678137B2 (fr)
CA (1) CA2115060C (fr)
CZ (1) CZ281796B6 (fr)
DE (1) DE69230403T2 (fr)
DK (1) DK0600970T3 (fr)
ES (1) ES2138976T3 (fr)
FI (1) FI940519A0 (fr)
GR (1) GR3032167T3 (fr)
HU (1) HU224437B1 (fr)
NO (1) NO315409B1 (fr)
PT (1) PT600970E (fr)
SK (1) SK282947B6 (fr)
WO (1) WO1993002693A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018783A1 (fr) * 1992-03-20 1993-09-30 Schering Corporation Utilisation d'interleukine 10 pour induire la production d'antagoniste des recepteurs de l'interleukine 1
WO1994006473A1 (fr) * 1992-09-18 1994-03-31 Schering Corporation Retablissement de l'immunosuffisance des lymphocytes t auxiliaires chez des patients contamines par le vih
WO1994017773A2 (fr) * 1993-02-01 1994-08-18 Université Libre de Bruxelles Utilisation d'une composition pharmaceutique comprenant une dose efficace d'interleukine-10, d'un analogue et/ou d'un agoniste d'interleukine-10
JPH08507930A (ja) * 1993-07-26 1996-08-27 シェリング・コーポレーション ヒトインターロイキン−１０のアゴニストおよびアンタゴニスト
AU686816B2 (en) 1994-07-05 1998-02-12 Steeno Research Group A/S Immunomodulators
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
JPWO2002066069A1 (ja) * 2001-02-20 2004-09-24 関西ティー・エル・オー株式会社 炎症・腫瘍性疾患治療剤
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
JP2013511994A (ja) 2009-11-30 2013-04-11 バイオテスト・アクチエンゲゼルシヤフト 全身性エリテマトーデス（ｓｌｅ）を治療するためのヒト化抗ｉｌ−１０抗体
BR112015018834A2 (pt) 2013-03-20 2017-07-18 Hoffmann La Roche método para a detecção de um anticorpo do rato, utilização de uma mistura de anticorpos monoclonais e utilização de um anticorpo

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
ZA9010188B (en) * 1989-12-20 1991-08-28 Schering Corp Bcrf1 proteins as inhibitors of interferon-gamma

Also Published As

Publication number Publication date
DE69230403D1 (de) 2000-01-13
HU224437B1 (hu) 2005-09-28
FI940519A7 (fi) 1994-02-04
JP2008013573A (ja) 2008-01-24
WO1993002693A2 (fr) 1993-02-18
SK12994A3 (en) 1994-12-07
NO315409B1 (no) 2003-09-01
KR100271197B1 (ko) 2000-11-01
PT600970E (pt) 2000-05-31
JP2004250454A (ja) 2004-09-09
GR3032167T3 (en) 2000-04-27
NO940370L (no) 1994-02-04
CZ281796B6 (cs) 1997-02-12
EP0541214A3 (en) 1993-09-08
DK0600970T3 (da) 2000-05-29
AU678137B2 (en) 1997-05-22
AU2441192A (en) 1993-03-02
CA2115060A1 (fr) 1993-02-18
HUT66865A (en) 1995-01-30
WO1993002693A3 (fr) 1993-07-22
EP0600970A1 (fr) 1994-06-15
CZ24394A3 (en) 1995-01-18
EP0541214A2 (fr) 1993-05-12
ES2138976T3 (es) 2000-02-01
ATE187336T1 (de) 1999-12-15
NO940370D0 (no) 1994-02-04
CA2115060C (fr) 2003-05-06
EP0600970B1 (fr) 1999-12-08
FI940519L (fi) 1994-02-04
DE69230403T2 (de) 2000-05-11
HU9400314D0 (en) 1994-05-30
FI940519A0 (fi) 1994-02-04
JPH07502019A (ja) 1995-03-02

Similar Documents

Publication Publication Date Title
US5837232A (en) Use of an interleukin-10 antagonist to treat a B cell mediated autoimmune disorder
Kishimoto B-cell stimulatory factors (BSFs): molecular structure, biological function, and regulation of expression
US5776451A (en) Use of interleukin-10 in adoptive immunotherapy of cancer
Kennedy et al. Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex
RU2120802C1 (ru) Фармацевтическая композиция, предназначенная для торможения зависимой от интерлейкина-2 пролиферации опухолевых клеток, увеличения содержания интерферона, лечения воспалительных заболеваний кишечника, потенцирования торможения производства цитокина и ограничения или торможения аллергической реакции замедленного типа
Galy et al. IL-1, IL-4, and IFN-gamma differentially regulate cytokine production and cell surface molecule expression in cultured human thymic epithelial cells
CA2062763C (fr) Facteur inhibiteur de la synthese de la cytokine, antagonistes dudit facteur, et methodes d'utilisation
JP2008013573A (ja) 内毒素または超抗原に誘導された毒性を治療するインターロイキン−１０類似体またはアンタゴニストの使用
CZ282523B6 (cs) Iterleukin - 10 pro léčení nádorů, farmaceutický prostředek jej obsahující, jeho použití a způsob výroby
EP0629130A1 (fr) Utilisation d'interleukine-10 pour supprimer des maladies provoquees par la reaction du greffon contre l'hote
US6207154B1 (en) Methods of treatment using antagonists of cytokine synthesis inhibitory factor
US6319493B1 (en) Treatment of neoplastic disease with interleukin-10
CA2079230C (fr) Antagonistes bcrf1 pour le traitement des infections dues au virus epstein-barr
O'Garra Cytokines and Their Role
IE902346L (en) Cytokine synthesis inhibitory factor

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20090806